Back to Journals » ClinicoEconomics and Outcomes Research » Volume 4

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

Total article views   HTML views PDF downloads Totals
14,223 Dovepress* 11,884+ 2,221 14,105
PubMed Central* 2,339 717 3,056
Totals 14,223 2,938 17,161
*Since 26 January 2012
+Since July 2016
Total mentioned Facebook Delicious Reddit Twitter Others
4 0 0 0 0 4

View citations on PubMed Central and Google Scholar